Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis Get access

• Abstract
• Lay summary
• Supplementary data

Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease Get access

• Abstract
• Lay summary

Letter: Enhancing the Rigor of Research on Herpes Zoster Risk in IBD Patients Post-SARS-CoV2: Recommendations for Global and Detailed Analyses—Authors’ Reply Get access

• Extract

Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review Get access

• Abstract
• Lay summary
• Supplementary data

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study Get access

• Abstract
• Lay summary

Treatment of Chronic Pouchitis With JAK Inhibitors: Results from A Large Multicenter Database Get access

Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019

• Abstract
• Lay summary
• Supplementary data

Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity

• Abstract
• Lay summary
• Supplementary data

Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis

• Abstract
• Lay summary
• Supplementary data

Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines

• Extract

Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study

• Abstract
• Supplementary data

Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis

Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease

• Extract

Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease

• Extract

Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease

Effect of 2 vs 3 Doses of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease: A Population-based Propensity Matched Analysis

• Abstract
• Supplementary data

A Note on Monkeypox for Our Patients With Inflammatory Bowel Disease

• Extract

Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination

• Abstract
• Lay summary

New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease

• Abstract
• Lay summary

Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease